Archive for June 5th, 2007
NSE Press Release
The Exchange has successfully completed its 1824th Normal Settlements (Rolling T+2 following SEBI directive) since inception i.e., Settlement Number N – 2007101 on June 4, 2007. The settlement statistics are as follows:
Particulars
|
Values
|
|
Total traded quantity (lakhs)
|
5020.91
|
|
Total traded value (Rs. In Crores)
|
11926.69
|
|
Total value of the settlement (Securities) (Rs. In Crores)
|
4047.27
|
|
Total value of the settlement (Funds) (Rs. In Crores)
|
1037.62
|
Shortages for the settlement
|
0.31%
|
|
% of Delivery ( No. of shares deliverable / No. of shares traded )
|
34.66%
|
Retail Debt Market have completed its 1098th settlements details of which are as follows:
| Settlement No. |
Traded Value |
Settlement Value
|
June 5th, 2007
NSE Press Release
The media had reports on June 02, 2007 that Fortis Healthcare Limited has set up a joint venture with DLF to set up hospitals across the country with an investment of Rs 6,200 crore.
The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.
Reply is awaited from Fortis Healthcare Limited.
June 5th, 2007
NSE Press Release
The media had reports on June 02, 2007 that Rallis India Ltd. may acquire a stake in Nagarjuna Fertilizers & Chemicals Limited.
The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the companies.
Nagarjuna Fertiliser & Chemicals Ltd. has vide its letter inter-alia stated,”The company totally denies the information published in the media in the matter of Rallis India acquiring stake in the Company.”
Reply is awaited from Rallis India Ltd.
June 5th, 2007
NSE Press Release
The media had reports on June 02, 2007 that Glenmark Pharmaceuticals Ltd. may announce a bonus issue.
The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.
Glenmark Pharmaceuticals Ltd. has vide its letter inter-alia stated, “We would like to clarify that the company has not decided regarding bonus issue and confirm that the company has not given any information regarding announcement of bonus issue to the media/ any other person and therefore we have no comments on the source of the news item.”
June 5th, 2007
NSE Press Release
The equity shares of the following company shall be listed and admitted to dealings on the Exchange w.e.f. June 6, 2007. Trading shall be in the Normal Market segment – Compulsory Demat (Rolling Settlement) for all investors.
|
Sr. No.
|
Symbol
|
Name of the Company
|
ISIN Code
|
June 5th, 2007
Next Posts